Werewolf Therapeutics (NASDAQ:HOWL) Director Sells $43,446.40 in Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Luke Evnin sold 67,885 shares of the stock in a transaction on Tuesday, May 12th. The shares were sold at an average price of $0.64, for a total transaction of $43,446.40. Following the completion of the sale, the director owned 1,171,175 shares of the company’s stock, valued at approximately $749,552. This represents a 5.48% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Luke Evnin also recently made the following trade(s):

• On Monday, May 11th, Luke Evnin sold 33,948 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.67, for a total transaction of $22,745.16.
• On Friday, May 8th, Luke Evnin sold 305,741 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.70, for a total transaction of $214,018.70.
• On Thursday, May 7th, Luke Evnin sold 79,086 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.63, for a total transaction of $49,824.18.
• On Wednesday, May 6th, Luke Evnin sold 14,635 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.66, for a total transaction of $9,659.10.
• On Tuesday, May 5th, Luke Evnin sold 6,860 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.69, for a total transaction of $4,733.40.
• On Monday, May 4th, Luke Evnin sold 47,963 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.72, for a total transaction of $34,533.36.
• On Friday, May 1st, Luke Evnin sold 58,394 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.73, for a total transaction of $42,627.62.
• On Thursday, April 30th, Luke Evnin sold 168,262 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.72, for a total transaction of $121,148.64.
• On Wednesday, April 29th, Luke Evnin sold 56,559 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.69, for a total transaction of $39,025.71.
• On Tuesday, April 28th, Luke Evnin sold 95,412 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.73, for a total transaction of $69,650.76.

Werewolf Therapeutics Trading Down 4.3%

HOWL traded down $0.03 during trading on Tuesday, reaching $0.63. 500,207 shares of the company’s stock were exchanged, compared to its average volume of 417,048. Werewolf Therapeutics, Inc. has a one year low of $0.53 and a one year high of $2.38. The stock has a market capitalization of $30.72 million, a PE ratio of -0.51 and a beta of 0.41. The firm has a fifty day moving average price of $0.81 and a two-hundred day moving average price of $0.83.

Werewolf Therapeutics (NASDAQ:HOWL) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.04. Sell-side analysts expect that Werewolf Therapeutics, Inc. will post -1.29 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages have commented on HOWL. Weiss Ratings reiterated a “sell (d-)” rating on shares of Werewolf Therapeutics in a research report on Monday, April 20th. Wall Street Zen cut shares of Werewolf Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday. Two equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $3.75.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Regal Investment Advisors LLC boosted its holdings in Werewolf Therapeutics by 93.3% in the fourth quarter. Regal Investment Advisors LLC now owns 52,593 shares of the company’s stock valued at $33,000 after acquiring an additional 25,389 shares in the last quarter. Vontobel Holding Ltd. lifted its position in Werewolf Therapeutics by 66.7% during the fourth quarter. Vontobel Holding Ltd. now owns 60,003 shares of the company’s stock valued at $38,000 after buying an additional 24,003 shares during the period. Qube Research & Technologies Ltd bought a new position in shares of Werewolf Therapeutics during the 2nd quarter valued at $48,000. AQR Capital Management LLC bought a new stake in shares of Werewolf Therapeutics during the 1st quarter valued at about $79,000. Finally, Bridgeway Capital Management LLC grew its stake in shares of Werewolf Therapeutics by 157.7% during the 2nd quarter. Bridgeway Capital Management LLC now owns 102,000 shares of the company’s stock valued at $111,000 after purchasing an additional 62,414 shares during the period. Institutional investors own 64.84% of the company’s stock.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.